Method for measuring atrial fibrillation index value

A metabolomics-based method using chromatography mass spectrometry measures specific metabolites as an atrial fibrillation index to enhance early and accurate diagnosis.

JP2024167397AActive Publication Date: 2024-12-03SHIMADZU SEISAKUSHO LTD

Patent Information

Application Number
JP2024152750
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-09-12
Filing Date
2024-09-04
Publication Date
2024-12-03
Estimated Expiration
2039-09-10

AI Technical Summary

Technical Problem

Current diagnostic methods for atrial fibrillation, such as ELISA, are limited in their ability to measure multiple disease markers simultaneously, making it difficult to diagnose the condition at an early stage effectively.

Method used

A method involving metabolomics analysis using chromatography mass spectrometry to measure specific metabolites like β-alanine, threonine, malic acid, and others as an atrial fibrillation index value, allowing comprehensive diagnosis of atrial fibrillation.

Benefits of technology

The method enables early and accurate diagnosis of atrial fibrillation by quantitatively measuring metabolites in biological samples, improving diagnostic accuracy and reducing misdiagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167397000001
    Figure 2024167397000001
  • Figure 2024167397000002
    Figure 2024167397000002
  • Figure 2024167397000003
    Figure 2024167397000003
Patent Text Reader

Abstract

To measure the amount of a metabolite considered to be related to atrial fibrillation, and in turn, make use of a result of measurement in diagnosing the atrial fibrillation.SOLUTION: The present invention is a method for measuring an atrial fibrillation index value, which is an index value related to the onset of atrial fibrillation. The method includes: analyzing an organism specimen harvested from a subject; and measuring, as the atrial fibrillation index value, the amount of at least one metabolite selected from among 16 types of metabolites, including β-alanine, threonine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, heptadecanoic acid, ribose, isocitric acid, phenylalanine, succinic acid, fucose, citric acid, and erythritol. A result of measuring the atrial fibrillation index value described above can be useful in diagnosing the atrial fibrillation.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for measuring substances associated with the onset of atrial fibrillation among substances contained in biological samples such as blood and urine. [Background technology]

[0002] Atrial fibrillation is a relatively common cardiac arrhythmia. The prevalence of atrial fibrillation increases with age, and in each age group, it is generally more prevalent in men than in women. In atrial fibrillation, rapid, irregular, and disorganized atrial excitation occurs, and effective atrial contraction is lost, causing stagnation of blood flow within the atrium and the formation of blood clots within the atrium. Cerebral embolism (cardiogenic cerebral infarction), which occurs due to the formation of blood clots within the atrium, is one of the serious complications of atrial fibrillation, and in many cases, permanent treatment with anticoagulants is required to prevent this.

[0003] In addition, atrial fibrillation reduces cardiac output because effective atrial contraction cannot be achieved. Therefore, when atrial fibrillation occurs in patients with heart disease, hemodynamics cannot be maintained and heart failure worsens. Furthermore, persistent tachycardia due to atrial fibrillation causes myocardial damage, which in the long term leads to a decline in cardiac function. Therefore, when atrial fibrillation occurs, it is important to use drug therapy with antiarrhythmic drugs, or non-drug therapies such as electrical defibrillation and catheter ablation to restore sinus rhythm early, prevent recurrence, and regulate heart rate (Non-Patent Document 1).

[0004] The standard method for diagnosing atrial fibrillation is a 12-lead electrocardiogram. However, because atrial fibrillation that occurs only occasionally, such as paroxysmal, is difficult to detect in a short test, a Holter monitor that can take electrocardiograms continuously for 24 hours is used. Furthermore, echocardiography is performed to rule out abnormalities in the heart valves. Risk factors for atrial fibrillation progressing from initial onset to persistent atrial fibrillation include heart failure, advanced age (75 years or older), a history of transient ischemic attack or cerebral infarction, chronic obstructive pulmonary disease, and hypertension (Non-Patent Document 2).

[0005] If atrial fibrillation could be diagnosed at a relatively early stage after its onset, not only would it be possible to prevent serious complications such as cerebral infarction, but it would also be possible to take prompt measures to maintain sinus rhythm. Furthermore, it would be useful for managing background factors that promote the transition to persistent atrial fibrillation (Non-Patent Document 3). Therefore, a disease marker that specifically captures the pre-onset or early stage of atrial fibrillation would be extremely useful for the treatment and prevention of atrial fibrillation. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Atrial fibrillation treatment (drug) guidelines (2013 revised edition). [Non-Patent Document 2] de Vos, CB et al. Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. J Am Coll Cardiol 55, 725-731 (2010) [Non-Patent Document 3] Aggressive Risk Factor Reduction Study for Atrial Fibrillation and Implications for the Outcome of Ablation: The ARREST-AF Cohort Study. J Am Coll Cardiol 64, 2222-2231 (2014) [Non-Patent Document 4] Schnabel, RB et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol. 104, 92-6 (2009) [Non-Patent Document 5] Mayr, M. et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol. 51, 585-94 (2008) [Non-Patent Document 6] Alonso A, Yu B, Qureshi WT, Grams ME, Selvin E, Soliman EZ, Loehr LR, Chen LY,Agarwal SK, Alexander D, Boerwinkle E. Metabolomics and Incidence of AtrialFibrillation in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One. 2015 Nov 6;10(11) [Non-Patent Document 7] Ehret, GB et al. International Consortium for Blood Pressure Genome-Wide Association Studies (ICBP-GWAS). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103-109 (2011) Summary of the Invention [Problem to be solved by the invention]

[0007] To date, inflammatory markers such as osteoprotegerin have been reported as disease markers associated with the onset of atrial fibrillation (Non-Patent Document 4). To detect these disease markers, a highly versatile immunological detection method called ELISA (Enzyme-Linked ImmunoSorbent Assay) is used. The immunological detection method is a method for measuring the target object individually and cannot measure multiple types of objects at once, so there are limitations to comprehensively searching for new disease markers with high specificity for the onset of atrial fibrillation.

[0008] In recent years, attempts have been made to search for various disease markers using metabolome analysis (metabolomics), which analyzes metabolites. There have been two reports so far on metabolome analysis in atrial fibrillation. One is a prospective study (follow-up study) reported by Mayr et al. in 2008 that combined metabolome analysis and proteome analysis using nuclear magnetic resonance spectroscopy (NMR). In this study, a group that developed atrial fibrillation after cardiac surgery was compared with a control group that maintained sinus rhythm, and changes in metabolites in atrial muscle tissue were observed in the atrial fibrillation group (Non-Patent Document 5). In the group that progressed to atrial fibrillation after cardiac surgery, uncoordinated changes in metabolites were observed in the atrial muscle tissue, and the presence of ketone bodies was suggested as a metabolite related to the onset of atrial fibrillation.

[0009] The other is the report of the ARIC (Atherosclerosis Risk in Communities) study by Alonso et al. in 2015, in which 1919 African-Americans were followed for 22 years and the serum of 183 subjects who developed atrial fibrillation was analyzed (Non-Patent Document 6). From the results of the analysis, metabolites related to the onset of atrial fibrillation were analyzed, and as a result, glycolithocholate sulfate and glycocholenate sulfate, which are related to the metabolism of bile acids, were reported as metabolites related to the onset of atrial fibrillation. Thus, although there have been reports of marker candidates related to the onset of atrial fibrillation, none of the marker candidates have been actually applied clinically.

[0010] Two factors are thought to be involved in the development of atrial fibrillation: genetic factors (genetic predisposition) and environmental factors (lifestyle habits) (Non-Patent Document 7). Genetic predisposition is important in terms of the susceptibility to disease onset, and it is thought that genetic information can be used as one of the disease markers to estimate the risk of developing a disease in the future, but it is difficult to diagnose a disease at an early stage based on genetic predisposition alone. In addition, lifestyle habits are important environmental factors just like genetic factors when they affect genetic predisposition, but lifestyle habits often change with age, and it is difficult to diagnose a disease that develops due to the overlap of a wide variety of factors at an early stage.

[0011] The problem to be solved by the present invention is to measure the amount of a metabolite thought to be associated with the onset of atrial fibrillation, and ultimately to utilize the measurement results in diagnosing atrial fibrillation. [Means for solving the problem]

[0012] The present invention, which has been made to solve the above problems, provides a method for measuring an atrial fibrillation index value, which is an index related to the onset of atrial fibrillation, comprising: The method is characterized in that a biological sample collected from a subject is analyzed, and the amount of at least one metabolite selected from 16 types of metabolites, namely β-alanine, threonine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, margaric acid, ribose, isocitrate, phenylalanine, succinic acid, fucose, citric acid, and erythritol, is measured as the atrial fibrillation index value.

[0013] In order to comprehensively grasp the complex pathological changes associated with atrial fibrillation, the present inventors used a technique called metabolomics to search for metabolites that serve as indicators of atrial fibrillation. Specifically, blood samples (serum) collected from many subjects were analyzed using a chromatographic mass spectrometer, and the amounts of many metabolites contained in the blood samples were comprehensively measured. By comprehensively analyzing the results, it was found that the above-mentioned 16 types of metabolites are closely related to atrial fibrillation. Therefore, at least one of the amounts of these 16 types of metabolites can be used as an atrial fibrillation indicator value for diagnosing atrial fibrillation.

[0014] The 16 metabolites mentioned above are metabolites that showed a high correlation with the presence or absence of atrial fibrillation as a result of statistical analysis of the measured values ​​of 135 robust metabolites among the many metabolites contained in serum, for two groups, one with and one without atrial fibrillation. Table 1 shows a list of the 135 metabolites. The names of the metabolites shown in Table 1, such as "-nTMS", "-nTMS(m)", "-methyloxime-nTMS", or "-methyloxime-nTMS(m)" (n and m are natural numbers), are derived from reagents added during analysis by a gas chromatograph mass spectrometer. Therefore, for example, "asparagine-2TMS" and "asparagine-3TMS" in Table 1 are derived from the same metabolite (asparagine). The presence or absence of atrial fibrillation in the two-group comparison was determined based on an electrocardiogram.

[0015] [Table 1]

[0016] Specifically, for example, the atrial fibrillation index value in the blood collected from the subject is measured, and the measured value is compared with a predetermined threshold value to determine whether or not the subject has atrial fibrillation.In this case, the range of the atrial fibrillation index value in the blood of the person diagnosed with atrial fibrillation (atrial fibrillation sufferer) and the person diagnosed not to have atrial fibrillation (normal person) is obtained in advance, and the subject's atrial fibrillation index value is determined based on whether the subject's atrial fibrillation index value is within the range of normal people or the range of people with atrial fibrillation.In addition, the range of the atrial fibrillation index value of the subject when healthy may be measured in advance, and the atrial fibrillation index value of the subject after that is compared with the range, and if the atrial fibrillation index value is outside the range, the subject's atrial fibrillation index value may be determined.

[0017] Although the atrial fibrillation index value, which is the measurement value of the above 16 kinds of metabolites, can be used alone to diagnose atrial fibrillation, the accuracy of diagnosing atrial fibrillation can be improved by using a combination of multiple atrial fibrillation index values. For example, it can be determined that the possibility of atrial fibrillation is higher when both of the two types of atrial fibrillation index values ​​are within a range indicating the onset of atrial fibrillation than when only one of the two types of atrial fibrillation index values ​​is within a range indicating the onset of atrial fibrillation.

[0018] In the present invention, the "biological sample collected from a subject" may be any sample, such as blood, biological tissue, feces, or urine, as long as the amount of metabolites contained in the biological sample can be measured. However, considering the ease of collecting the sample and the large amount of metabolites contained therein, blood (whole blood, serum, or plasma) is preferred. As serum, a liquid component obtained by coagulating blood cell components without adding an anticoagulant to whole blood can be used. Furthermore, as plasma, a liquid component obtained by adding an anticoagulant to whole blood without coagulating blood cell components can be used.

[0019] In addition, chromatographic mass spectrometry (chromatographic MS analysis) was used to search for metabolites related to the onset of atrial fibrillation, but the analytical method of the biological sample in the present invention is not limited to chromatographic MS analysis, and may be an immunological analysis method such as nuclear magnetic resonance (NMR) spectroscopy, enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA). However, chromatographic MS analysis is superior in that it can quantitatively measure the amount of metabolites contained in the biological sample. Chromatographic MS analysis refers to an analysis using a gas chromatograph or liquid chromatograph and a mass analyzer as a detector for the sample separated by these chromatographs. Examples of mass analyzers include a triple quadrupole mass analyzer, a Q-TOF mass analyzer, a TOF-TOF mass analyzer, an ion trap mass analyzer, and an ion trap time-of-flight mass analyzer. These mass spectrometers enable highly sensitive analysis of samples that contain many impurities other than the analyte (metabolites), and improve analytical stability, making it possible to quantitatively measure the amount of metabolites contained in biological samples with high reproducibility.

[0020] In the above-mentioned method for measuring an atrial fibrillation index value, The atrial fibrillation index value is preferably the amount of any one of the 16 metabolites, particularly isocitrate, arabinose, ribose, 2-oxoglutaric acid, malic acid, phenylalanine, fumaric acid, succinic acid, fucose, and citric acid.

[0021] The above 10 kinds of metabolites were found to have significant differences between the two groups, the group with AF (atrial fibrillation) and the normal group (without AF), when a t-test was performed between the two groups for the measured values ​​of 135 kinds of metabolites. In addition, the P value of these was less than 0.001 in a separate Mann-Whitney U test. Therefore, the amount of the above 10 kinds of metabolites can be measured as an atrial fibrillation index value, and the presence or absence of atrial fibrillation can be diagnosed by comparing the index value with a predetermined threshold value. The predetermined threshold value can be the average value or median value when the amount of each of the above 10 kinds of metabolites contained in the biological sample of a large number of subjects is measured.

[0022] The atrial fibrillation index value is preferably the amount of any one of the metabolites, particularly β-alanine, fumaric acid, threonine, succinic acid, and 2-oxoglutaric acid, among the 16 types of metabolites. The above five metabolites were analyzed by logistic regression analysis of the measured values ​​of 135 metabolites in a model that included the presence or absence of atrial fibrillation as the dependent variable, as well as age, sex, smoking history, current history of hypertension or diabetes, past history of heart disease, and eGFR value as adjustment factors. The P value was less than 0.05, and these metabolites showed a high correlation with the presence or absence of atrial fibrillation. Therefore, by measuring the measured values ​​of these five metabolites as atrial fibrillation index values ​​and comparing them with a specified threshold, atrial fibrillation can be diagnosed at an early stage.

[0023] In addition, the atrial fibrillation index value is preferably the amount of any one of the 16 metabolites, particularly 2-oxoglutaric acid, isocitrate, fucose, arabinose, fumaric acid, erythritol, succinic acid, phenylalanine, malic acid, and citric acid. The above 10 types of metabolites were the ones with the largest AUC values ​​when the measured values ​​of 135 types of metabolites were analyzed using ROC analysis with the presence or absence of atrial fibrillation as the dependent variable. Therefore, by measuring the measured values ​​of these 10 types of metabolites as atrial fibrillation index values ​​and comparing them with a predetermined threshold, the presence or absence of atrial fibrillation can be diagnosed and misdiagnosis can be reduced.

[0024] Furthermore, the atrial fibrillation index value is preferably the amount of any one of the 16 metabolites, particularly β-alanine, threonine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, margaric acid, and ribose. The above 10 metabolites were the ones with the largest C-statistics when the measured values ​​of 135 metabolites were calculated for a model that included the presence or absence of atrial fibrillation as the dependent variable, and age, sex, smoking history, current history of hypertension or diabetes, past history of heart disease, and eGFR value as adjustment factors. Therefore, by measuring the measured values ​​of these 10 metabolites as atrial fibrillation index values ​​and comparing them with a specified threshold, the presence or absence of atrial fibrillation can be diagnosed with high accuracy. Effect of the Invention

[0025] In the present invention, metabolomics analysis techniques are used to search for metabolites that are highly associated with atrial fibrillation, and the amounts of the metabolites found in a biological sample are measured as an atrial fibrillation index value, which can be used to diagnose atrial fibrillation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] The present inventor analyzed biological samples (serum) collected from subjects using a gas chromatograph mass spectrometer (GCMS) and comprehensively measured the amounts of many metabolites contained in the biological samples. Then, by analyzing the measured values ​​using various techniques, metabolites thought to be closely related to the presence or absence of atrial fibrillation were searched for. Table 2 shows the baseline characteristics of subjects from whom biological samples were collected to search for metabolites related to the onset of atrial fibrillation. The method of extracting subjects whose baseline characteristics are shown in Table 2, the method of preparing and analyzing biological samples, the method of measuring metabolites, and the analysis of the measurement results are described below.

[0027] [Table 2]

[0028] <Selection of subjects> With the approval of the research ethics committee, 7,601 patients were randomly sampled from among those who visited the St. Luke's International Hospital Attached Clinic Preventive Medicine Center between October 2015 and September 2016 (approximately 45,000 people), and those who declined to participate in the study were excluded, leaving 7,592 subjects as subjects. All subjects were provided with a self-administered questionnaire about their medical history and lifestyle habits (smoking, etc.). In addition, the subjects' height, weight, body mass index (BMI), blood pressure, and blood test results (hemoglobin A1c, fasting blood glucose, creatinine (estimated GFR)) were also provided at the time of the medical checkup.

[0029] The St. Luke's International Hospital Attached Clinic Preventive Medicine Center is located in Chuo-ku, Tokyo, and many of the people undergoing health checkups live in the Tokyo area. All subjects in this study were Japanese. Therefore, the subjects in this study can be said to be a homogenous group in terms of both environmental and ethnic factors.

[0030] The median age of the 7,592 subjects was 52 years (interquartile range 42-62 years), of which 3,967 (52.3%) were women. In addition, 58 subjects (0.8%) were diagnosed with atrial fibrillation (AF) by electrocardiogram (referred to as the "AF group"), and 7,534 subjects (99.2%) were not diagnosed with AF (referred to as the "normal group"). As shown in Table 2 above, there were statistically significantly more men than women in the AF group, and the AF group was statistically significantly older than the normal group.

[0031] <Sample preparation> (1) Pretreatment The blood collected from the subjects was left to stand for a specified period of time, then centrifuged and the supernatant (serum) was collected. The collected serum was stored at -80°C until analysis. Note that the time between when blood was collected from the subjects and when the serum was frozen affects the measured values ​​of metabolites in the serum. For approximately half of the subjects in this study, the time between when blood was collected and when it was frozen was 5 to 8 hours.

[0032] (2) Main Processing Serum stored at -80°C was thawed at 25°C for 5 minutes. The thawed serum was centrifuged at 10,000×g, 4°C, 1 minute, and then allowed to stand on ice. 250 μL of the first mixed solution (methanol / water / chloroform, 2.5:1:1) was mixed with 6 μL of an internal standard solution (2-isopropylmalic acid: 0.1 mg / mL), and the mixture was mixed using a vortex mixer to obtain a second mixed solution.

[0033] The serum and the second mixture were then shaken at 1,200 rpm at 37°C for 30 minutes, and then centrifuged at 16,000 x g at 25°C for 5 minutes. 150 μL of the supernatant was added to a tube to which 140 μL of water had previously been added, and mixed using a vortex mixer to obtain a third mixture. Next, the third mixture was centrifuged at 16,000×g for 5 minutes at 25° C., and 180 μL of the supernatant was collected in a new tube. This was concentrated in a centrifugal evaporator at room temperature for 60 minutes with the speed memory set to “7”. The supernatant of the concentrated third mixture (concentrated solution) was frozen at -80°C for 30 minutes, and then dried overnight to prepare a sample. The obtained sample was stored in a desiccator until analysis.

[0034] <GCMS analysis of samples> To the sample stored in a desiccator, 80 μL of methoxyamine solution (20 mg / mL, dissolved in pyridine) was added, and the mixture was shaken at 1,200 rpm for 30 minutes at 37° C. Then, 40 μL of N-methyl-N-trimethylsilyltrifluoroacetamide was added, and the mixture was shaken at 1,200 rpm for 30 minutes at 37° C., followed by centrifugation at 16,000×g for 5 minutes at 25° C., and 50 μL of the supernatant was placed in a glass vial, which was then set in the autosampler of the GCMS.

[0035] For the GCMS, a triple quadrupole gas chromatograph mass spectrometer (GCMS-TQ8040) manufactured by Shimadzu Corporation was used. The analytical conditions for the GCMS are as follows: (1) Column: DB-5 ((5%-phenyl)-methylpolysiloxane, non-polar), length 30 m, inner diameter 0.25 mm, film thickness 1.00 μm (2) Column oven temperature: 80°C (3) Injection temperature: 280℃ (4) Injection mode: Split (5) Helium gas flow rate: 39 cm / sec (6) Column temperature: 0-2.5 min; 80°C, 2.5-18.5 min; increase to 80-280°C, 18.5-23.0 min; 280°C (7) MS ion source temperature: 200°C (8) Interface temperature: 250℃ (9) Detector voltage: 0.2 kV (10) Mass range: m / z 85-500

[0036] <Data Analysis> <Metabolite measurement> Peaks were comprehensively detected from the mass spectrum of the sample, and the peak information (mass-to-charge ratio and signal intensity) was compared with the mass-to-charge ratios of numerous metabolite-specific substances stored in the MS library to identify the metabolites, and measurement values ​​(hereinafter referred to as MS data) for 135 types of metabolites were obtained.

[0037] <Statistical analysis> For subjects who had MS data, the clinical information and test data necessary for statistical analysis were obtained from the Information Systems Center of St. Luke's International University with the consent of the Research Ethics Committee of St. Luke's International Hospital, and the clinical information and test data were matched with the MS data. All clinical information and test data of subjects were managed by a management number that identifies the subject, so that subjects could not be identified when matching the data.

[0038] For statistical analysis, unpaired t-test and Mann-Whitney U test were used for univariate analysis, and logistic regression analysis was used for multivariate analysis. Diagnostic ability was evaluated using the AUC value calculated from the ROC curve for models of each metabolite alone, and the C statistic for multivariate analysis models using adjustment factors.

[0039] Table 3 shows the results of a t-test performed on the AF and normal groups for the amounts of 135 metabolites measured in both groups. Table 3 lists the P values ​​and t-statistics for 10 metabolites (isocitric acid, arabinose, ribose, 2-oxoglutaric acid, malic acid, phenylalanine, fumaric acid, succinic acid, fucose, and citric acid) that showed statistically significant differences between the AF and normal groups, in order of smallest P value. In Table 3, "mEn (m is a real number, n is an integer)" is expressed as "m x 10 n " For example, "3.74E-06" means "3.74 x 10 -6 The ten metabolites shown in Table 3 all had a P value of less than 0.001 in a separate Mann-Whitney U test.

[0040] [Table 3]

[0041] As shown in Table 3, for all 10 metabolites, the smaller the P value, the larger the absolute value of the t-statistic, and all were negative except for ribose. This shows that the amounts of the nine metabolites, except for ribose, were statistically significantly lower in the normal group than in the AF group, and the amount of ribose was statistically significantly higher in the normal group than in the AF group. From the above results, the measured values ​​of the above 10 metabolites are useful as atrial fibrillation indicators, and the measured values ​​can be compared with a predetermined threshold value, and when they are greater or smaller than the threshold value, atrial fibrillation can be diagnosed.

[0042] Table 4 shows the results of a logistic regression analysis of the association between the AF group and the measured values ​​of 135 in vivo metabolites, with the AF group / normal group as the dependent variable and age, sex, smoking history, current history of hypertension / diabetes, history of heart disease, and eGFR (estimate glomerular filtration rate) as adjustment factors. Table 4 lists the five metabolites (β-alanine, fumaric acid, threonine, succinic acid, and 2-oxoglutaric acid) with the smallest P value as a result of the logistic regression analysis, along with the regression coefficient, standard error, and P value. As shown in Table 4, β-alanine had the smallest P value among the five metabolites, and a strong correlation was observed between β-alanine and atrial fibrillation. Table 4 also shows the t-statistic, P value, and t-test P value ranking, which are the results of the t-test when adjustments were not made with adjustment factors. The P-value ranking of the above five metabolites was higher when adjusted with the adjustment factor than when not adjusted with the adjustment factor. Thus, adjusting with the adjustment factor raised the ranking, and increased the usefulness as an index.

[0043] [Table 4]

[0044] Next, to examine the diagnostic ability (i.e., the diagnostic accuracy of atrial fibrillation) when the measured values ​​of each metabolite were used as the atrial fibrillation index value, receiver operating characteristic analysis (ROC analysis) was performed on 135 metabolites with the dependent variable being the AF group / normal group. As a result, it was found that the measured values ​​of 10 metabolites (2-oxoglutaric acid, isocitrate, fucose, arabinose, fumaric acid, erythritol, succinic acid, phenylalanine, malic acid, and citric acid) are useful for diagnosing atrial fibrillation. Table 5 shows the AUC values ​​of the ROC curves of the 10 metabolites useful for diagnosing atrial fibrillation.

[0045] [Table 5]

[0046] The ROC curve is plotted with the true positive rate, or sensitivity, on the vertical axis and the false positive rate, or "1-specificity" on the horizontal axis. In other words, the sensitivity is calculated from the proportion of subjects judged to be positive to all subjects with atrial fibrillation, and the false positive rate is calculated from the proportion of subjects judged to be positive (non-AF) to all subjects in the normal group. The ROC curve is obtained by calculating the sensitivity and false positive rate at other cutoff values ​​in the same way and plotting the values ​​obtained in this way on a graph. The AUC value is the value of the area surrounded by the ROC curve and the horizontal axis. The larger the AUC value, the higher the accuracy of diagnosing the presence or absence of AF. When the AUC value was calculated from the ROC curve, the endogenous metabolites with the largest AUC values ​​were 2-oxoglutaric acid (AUC = 0.733), isocitrate (AUC = 0.723), and fucose (AUC = 0.722).

[0047] On the other hand, Table 6 shows the 10 metabolites with the highest C-statistics as a result of ROC analysis of 135 metabolites for a model in which the same dependent variables as those in the ROC analysis that obtained the results shown in Table 5 were used, and age, sex, smoking history, current history of hypertension or diabetes, history of heart disease, and eGFR value were used as adjustment factors. The C-statistics corresponds to the AUC value, and the closer the C-statistics is to 1, the higher the diagnostic ability. Table 6 lists the 10 metabolites (β-alanine, threonine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, margaric acid, and ribose) with the highest C-statistics among the 135 metabolites, along with their C-statistics. The measured values ​​of these 10 metabolites are all statistically correlated with atrial fibrillation, and are useful as indicators for diagnosing the presence or absence of atrial fibrillation. In particular, the measurement value of β-alanine (C statistic: 0.917), which had the largest C statistic, showed a strong correlation with atrial fibrillation and can be said to be an excellent indicator for diagnosing the presence or absence of atrial fibrillation.

[0048] [Table 6]

[0049] Table 6 also lists the AUC values ​​and AUC rankings obtained by ROC analysis when adjustments were not made with adjustment factors. The AUC rankings of the above 10 metabolites were higher when adjusted with adjustment factors than when not adjusted with adjustment factors. In this way, adjustments with adjustment factors raise the rankings of the 10 metabolites, increasing their usefulness as indicators.

[0050] In this way, the results of measuring the amounts of 16 types of metabolites contained in a biological sample from a subject can be used to diagnose the presence or absence of atrial fibrillation in the subject. That is, a method for diagnosing atrial fibrillation includes analyzing a biological sample collected from a subject using an analytical device, determining an atrial fibrillation index value, which is the amount of at least one metabolite selected from 16 types of metabolites, namely, β-alanine, threonine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, margaric acid, ribose, isocitrate, phenylalanine, succinic acid, fucose, citric acid, and erythritol, from the data obtained by the analytical device, and diagnosing the presence or absence of atrial fibrillation in the subject based on the results of comparing the atrial fibrillation index value with a predetermined threshold value.

[0051] Another method for diagnosing atrial fibrillation includes analyzing a biological sample collected from a subject using a chromatography mass spectrometer, determining an atrial fibrillation index value, which is the amount of at least one metabolite selected from 16 types of metabolites, namely, β-alanine, threonine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, margaric acid, ribose, isocitrate, phenylalanine, succinic acid, fucose, citric acid, and erythritol, from the data obtained by the chromatography mass spectrometer, and diagnosing the presence or absence of atrial fibrillation in the subject based on the results of comparing the atrial fibrillation index value with a predetermined threshold.

Claims

1. A method for measuring an atrial fibrillation index value, which is an index related to the onset of atrial fibrillation, comprising: A method for measuring an atrial fibrillation index value, comprising analyzing a biological sample collected from a subject and measuring the amount of threonine, which is a metabolite, as the atrial fibrillation index value.

2. 2. The method for measuring an atrial fibrillation index value according to claim 1, A method for measuring an atrial fibrillation index value, wherein the atrial fibrillation index value is a combination of an amount of threonine and an amount of any one of metabolites selected from the group consisting of β-alanine, fumaric acid, and 2-oxoglutaric acid.

3. 2. The method for measuring an atrial fibrillation index value according to claim 1, A method for measuring an atrial fibrillation index value, wherein the atrial fibrillation index value is a combination of the amount of threonine and the amount of any one of metabolites selected from the group consisting of β-alanine, malic acid, fumaric acid, 2-hydroxypyridine, 2-oxoglutaric acid, serine, arabinose, margaric acid, and ribose.

4. The method for measuring an atrial fibrillation index value according to any one of claims 1 to 3, A method for measuring an atrial fibrillation index value, wherein the atrial fibrillation index value is an amount of a metabolite measured based on data obtained by subjecting a biological sample to chromatographic MS analysis.

Citation Information

Patent Citations

  • Method for diagnosing heart failure

    US20150090010A1

  • Evaluation method, evaluation device, evaluation program, evaluation system, and terminal device

    WO2016056631A1

Cited By

  • Nervous system cell-containing spheroid, method for producing nervous system cell-containing spheroid, and method for evaluating test substance

    EP4613846A1